-
Health care organizations everywhere are using focus groups of consumers to critique services, rate educational materials, offer feedback on patient safety, or register kudos and gripes about the quality of patient care.
-
Serious adverse events can result when unauthorized family members, caregivers, or clinicians administer patient-controlled analgesia (PCA) for the patient by proxy, warns a Sentinel Event Alert issued by the JCAHO.
-
Imagine the moment when surveyors leave after your next Joint Commission on Accreditation of Healthcare Organizations (JCAHO) survey or when you just have submitted your organizations periodic performance review (PPR). You may be tempted to breathe a sigh of relief but if noncompliant areas are identified, your work has just begun.
-
If youre expecting that the Joint Commission on Accreditation of Healthcare Organizations proposed revisions to medication management standards will add to your workload, youre probably right.
-
Developers of a new web site for researchers and IRB administrators hope it will help streamline review of multisite research by centralizing protocol creation and enhancing communication among research sites.
-
After sometimes traumatic deliveries, mothers are exhausted, and perhaps on medication. Fathers are frantic with worry about both mother and baby. Some question whether its even possible to get true informed consent for research under those circumstances.
-
A new computerized tool developed at Vanderbilt University in Nashville, TN, provides investigators with information about IRB policies and human subject research regulations at a critical point in the research process when theyre filling out their IRB applications.
-
The work of IRBs will not get easier this year, if predictions from panelists at the fall Public Responsibility in Medicine & Research (PRIM&R) conference are on point. Some issues are old hat informed consent, conflict of interest and others will arise out of the new frontier of stem cell research.
-
The revelation that Mercks popular painkiller rofecoxib (Vioxx), as well as other drugs in the COX-2 inhibitor class, pose an increased risk of heart attack and stroke in patients who take them has led many in the research community to question whether the instiutional review boards at the sites where the drug was tested failed in their mission.
-
In this Q&A, Bernard Schwetz, DVM, PHD, director of the Office of Human Research Protections (OHRP), discusses the Belmont Reports successes and challenges as the 25th anniversary of its launching has passed.